- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07681258
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region (ASC4Young)
ASC4Young: Real-World Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chronic myeloid leukemia (CML) across the Gulf region. The data source for this study will consist of routinely collected clinical information documented within the electronic health records (EHR) of participating centers.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: +41613241111
- E-mail: novartis.email@novartis.com
Sauvegarde des contacts de l'étude
- Nom: Novartis Pharmaceuticals
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
CML patients who initiate asciminib between 01 May 2023 and 31 May 2026 in participating centers across the Gulf region.
La description
Inclusion Criteria
- Confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)
- Adult patients aged ≥ 18 years at the index date (or adult as defined by applicable national regulations)
- Documented exposure to asciminib during the identification period (May 2023 to May 2026)
- Provision of signed informed consent for secondary use of data, or an ethics committee-approved waiver of consent, where applicable (including for deceased patients or where data were previously collected within the EHR system)
Exclusion Criteria
- Patients who do not meet the eligibility criteria specified above
- Patients with insufficient medical record documentation to determine asciminib exposure or key study outcomes
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: RETROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Young Adults Cohort
CML patients aged ≤ 40 years at the first documented asciminib administration. |
|
Older Adults Cohort
CML patients aged > 40 years at the first documented asciminib administration. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Major Molecular Response (MMR) Rate in Young Adults
Délai: Approximately 12 Months
|
MMR is defined as a BCR::ABL1 level on the International Scale (BCR::ABL1 IS) ≤ 0.1%. |
Approximately 12 Months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Adverse Events (AEs)
Délai: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Treatment Interruptions Due to AEs
Délai: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions Due to AEs
Délai: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Time to Treatment Discontinuation due to Adverse Events (TTDAE)
Délai: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 10% After 3 Months of Treatment
Délai: 3 months
|
3 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 1% After 6 Months of Treatment
Délai: 6 months
|
6 months
|
|
|
Number of Patients With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
Délai: Up to 12 months prior to Baseline
|
Up to 12 months prior to Baseline
|
|
|
Duration of CML at Time of Asciminib Treatment Initiation
Délai: Baseline
|
Baseline
|
|
|
Asciminib Starting Dose
Délai: Baseline
|
Baseline
|
|
|
Number of Treatment Interruptions
Délai: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions
Délai: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reasons for Treatment Interruptions and Subsequent Treatment Switching
Délai: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reason for Treatment Switch
Délai: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Type and Severity of AEs
Délai: Approximately 3, 6, and 12 months
|
Number of patients by type and severity of AEs including serious AEs and grade ≥ 3 AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Approximately 3, 6, and 12 months
|
|
Incidence of AEs Leading to Dose Modifications
Délai: Approximately 3, 6, and 12 months
|
Dose modifications include treatment interruptions and dose reductions. |
Approximately 3, 6, and 12 months
|
|
MMR in Patients Aged > 40 years
Délai: Approximately 12 months
|
MMR is defined as BCR::ABL1 IS ≤ 0.1%. |
Approximately 12 months
|
|
Rate of Deep Molecular Response
Délai: Approximately 12 months
|
Deep molecular response includes:
|
Approximately 12 months
|
|
Number of Patients With Dose Modifications
Délai: Approximately 3, 6, and 12 months
|
Number of patients with dose modifications including up titration or dose reduction. |
Approximately 3, 6, and 12 months
|
|
Number of Patients by Clinicopathological Characteristics
Délai: Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
Clinicopathological characteristics include:
|
Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs
- Maladie chronique
- Attributs de la maladie
- Tumeurs par type histologique
- Maladies hématologiques
- Leucémie myéloïde
- Maladies de la moelle osseuse
- Leucémie
- Troubles myéloprolifératifs
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Leucémie, myéloïde, chronique, BCR-ABL positif
Autres numéros d'identification d'étude
- CABL001J1AE01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .